Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?

Attention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric illness, which affects about 5% of children worldwide. An 80% genetic background is responsible for ADHD due to its appearance in familial relationships. In addition, dopamine regulation in synaptic spaces, which hav...

Full description

Bibliographic Details
Main Authors: Fatemeh Moharrari, Soheila Barabadian
Format: Article
Language:English
Published: Mashhad University of Medical Sciences 2015-01-01
Series:Reviews in Clinical Medicine
Subjects:
Online Access:http://rcm.mums.ac.ir/pdf_3875_9ad255575acfb89b67187cb307c03aba.html
_version_ 1828349564859449344
author Fatemeh Moharrari
Soheila Barabadian
author_facet Fatemeh Moharrari
Soheila Barabadian
author_sort Fatemeh Moharrari
collection DOAJ
description Attention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric illness, which affects about 5% of children worldwide. An 80% genetic background is responsible for ADHD due to its appearance in familial relationships. In addition, dopamine regulation in synaptic spaces, which have a central role in development of ADHD, is moderated by dopamine transporter neurotransmitter, which in turn is modulated by dopamine transporter gene named SLC6A3 or DAT1. Methylphenidate as the first line and most important prescribed medication for ADHD blocks dopamine transporter and increases the dopamine concentration in synaptic clefts. In theory, methylphenidate relay to dopamine transporter to play a role, and dopamine transporter synthesis is dependent on DAT1. This gene have 40 base pair in its 3`-untranslated region end that repeat from 3 to 11 times, with most frequent 9 and 10 repeats in human, forming several alleles in carriers including 9R and 10R and genotypes including 9R/9R, 10R/10R, 9R/10R. These genotypes, as the first suspected candidates, may explain why methylphenidate therapy is not sufficient some patients and how the side effects appear in some cases and not in all patients. Many studies have performed to investigate the association between responses to methylphenidate and genotypes and yet no consistency has occurred. This article has a rapid review on concerned literature.
first_indexed 2024-04-14T01:11:24Z
format Article
id doaj.art-b6453816da1d47b9ab0119c0f559f20d
institution Directory Open Access Journal
issn 2345-6256
2345-6892
language English
last_indexed 2024-04-14T01:11:24Z
publishDate 2015-01-01
publisher Mashhad University of Medical Sciences
record_format Article
series Reviews in Clinical Medicine
spelling doaj.art-b6453816da1d47b9ab0119c0f559f20d2022-12-22T02:21:01ZengMashhad University of Medical SciencesReviews in Clinical Medicine2345-62562345-68922015-01-012265713875Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?Fatemeh Moharrari0Soheila Barabadian1Psychiatry and Behavioral Sciences Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranPsychiatry and Behavioral Sciences Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAttention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric illness, which affects about 5% of children worldwide. An 80% genetic background is responsible for ADHD due to its appearance in familial relationships. In addition, dopamine regulation in synaptic spaces, which have a central role in development of ADHD, is moderated by dopamine transporter neurotransmitter, which in turn is modulated by dopamine transporter gene named SLC6A3 or DAT1. Methylphenidate as the first line and most important prescribed medication for ADHD blocks dopamine transporter and increases the dopamine concentration in synaptic clefts. In theory, methylphenidate relay to dopamine transporter to play a role, and dopamine transporter synthesis is dependent on DAT1. This gene have 40 base pair in its 3`-untranslated region end that repeat from 3 to 11 times, with most frequent 9 and 10 repeats in human, forming several alleles in carriers including 9R and 10R and genotypes including 9R/9R, 10R/10R, 9R/10R. These genotypes, as the first suspected candidates, may explain why methylphenidate therapy is not sufficient some patients and how the side effects appear in some cases and not in all patients. Many studies have performed to investigate the association between responses to methylphenidate and genotypes and yet no consistency has occurred. This article has a rapid review on concerned literature.http://rcm.mums.ac.ir/pdf_3875_9ad255575acfb89b67187cb307c03aba.htmlAttention-deficit/hyperactivity disorderMethylphenidatePolymorphism
spellingShingle Fatemeh Moharrari
Soheila Barabadian
Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?
Reviews in Clinical Medicine
Attention-deficit/hyperactivity disorder
Methylphenidate
Polymorphism
title Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?
title_full Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?
title_fullStr Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?
title_full_unstemmed Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?
title_short Is dopamine transporter gene effective on therapeutic response of methylphenidate in ADHD patients?
title_sort is dopamine transporter gene effective on therapeutic response of methylphenidate in adhd patients
topic Attention-deficit/hyperactivity disorder
Methylphenidate
Polymorphism
url http://rcm.mums.ac.ir/pdf_3875_9ad255575acfb89b67187cb307c03aba.html
work_keys_str_mv AT fatemehmoharrari isdopaminetransportergeneeffectiveontherapeuticresponseofmethylphenidateinadhdpatients
AT soheilabarabadian isdopaminetransportergeneeffectiveontherapeuticresponseofmethylphenidateinadhdpatients